CD44 Isoform 6 (CD44v6) Is a Prognostic Indicator of the Response to Neoadjuvant Chemotherapy in Cervical Carcinoma
- 1 January 2001
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 80 (1) , 67-73
- https://doi.org/10.1006/gyno.2000.6016
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Time to add chemotherapy to radiotherapy for cervical cancerThe Lancet, 1999
- EXPRESSION AND PROGNOSTIC VALUE OF CD44 ISOFORMS IN TRANSITIONAL CELL CARCINOMA OF RENAL PELVIS AND URETERJournal of Urology, 1999
- EXPRESSION AND PROGNOSTIC VALUE OF CD44 ISOFORMS IN TRANSITIONAL CELL CARCINOMA OF RENAL PELVIS AND URETERJournal of Urology, 1999
- Neoadjuvant Chemotherapy in Stage IB2 Squamous Cell Carcinoma of the CervixGynecologic Oncology, 1997
- Prognostic Factors in Patients with Bulky Stage IB or IIA Cervical Carcinoma Undergoing Neoadjuvant Chemotherapy and Radical HysterectomyGynecologic Oncology, 1997
- E-Cadherin and Integrin Cell Adhesion Molecule Expression in Invasive andin SituCarcinoma of the CervixGynecologic Oncology, 1997
- The Expression Patterns of Standard and Variant CD44 Molecules in Normal Uterine Cervix and Cervical CancerGynecologic Oncology, 1997
- Neoadjuvant Chemotherapy with Vincristine and Cisplatin Followed by Radical Hysterectomy and Pelvic Lymphadenectomy for FIGO Stage IB Bulky Cervical Cancer: A Gynecologic Oncology Group Pilot StudyGynecologic Oncology, 1995
- The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCRJournal of General Virology, 1995
- Strategies for global control of cervical cancerInternational Journal of Cancer, 1995